Table 1.
Summary of the 5 studies comparing immunotherapy with docetaxel in patients with locally advanced or metastatic, previously treated non-small cell lung cancer.
| Study | No. of patients | Study time | Immunotherapy | Chemotherapy | Median overall survival (months) | Median progression-free survival (months) | ||
|---|---|---|---|---|---|---|---|---|
| Immunotherapy | Chemotherapy | Immunotherapy | Chemotherapy | |||||
| Nivolumab vs. Docetaxel | ||||||||
| Borghaei et al. 2015 | 582 | 2012.11-2013.12 | 3 mg/kg every 2 weeks | 75 mg/m2 every 3 weeks | 12.2 | 9.4 | 2.3 | 4.2 |
| Brahmer et al. 2015 | 272 | 2012.10-2013.12 | 3 mg/kg every 2 weeks | 75 mg/m2 every 3 weeks | 9.2 | 6.0 | 3.5 | 2.8 |
| Pembrolizumab vs. Docetaxel | ||||||||
| Herbst et al. 2016 | 1034 | 2013.08-2015.02 | Arm 1: 2 mg/kg every 3 weeks Arm 2: 10 mg/kg every 3 weeks |
75 mg/m2 every 3 weeks | 14.9 for arm 1; 17.3 for arm 2 |
8.2 | 3.9 for arm 1; 4.0 for arm 2 |
4.0 |
| Atezolizumab vs. Docetaxel | ||||||||
| Fehrenbacher et al. 2016 | 287 | 2013.08-2014.03 | 1200 mg ever 3 weeks | 75 mg/m2 every 3 weeks | 12.6 | 9.7 | 2.7 | 3.0 |
| Rittmeyer et al. 2017 | 850 | 2014.03-2015.04 | 1200 mg ever 3 weeks | 75 mg/m2 every 3 weeks | 12.6 | 8.9 | 2.8 | 4.0 |